Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Sequential Trial of Agents Against DNA Repair (STAR)

NCT04197713 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04197713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04197713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Sequential Trial of Agents Against DNA Repair (STAR)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 30, 2020
Completion date
December 31, 2026
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, metastatic malignant solid neoplasm, refractory malignant solid neoplasm, unresectable malignant solid neoplasm